Eli Lilly's Q1 2026 earnings conference call centered on retatrutide's first positive Phase III data in type 2 diabetes and a sweeping in vivo cell therapy acquisition strategy, as the US giant moves to simultaneously defend its incretin franchise while building a post-incretin pipeline through modality diversification. The call was held on April 30, 2026.
Key Strategic Signals
Retatrutide (GIP/GLP-1/glucagon triple agonist): The company reported positive top-line results from TRANSCEND-T2D-1, the first Phase III trial of retatrutide in type 2 diabetes, showing hemoglobin A1c reductions of 1.7 to 2.0 percentage points across doses and weight loss of 11.1 to 16.6 kilograms. Chief Scientific and Product Officer Daniel Skovronsky said the data suggest retatrutide can deliver glycemic control comparable to tirzepatide while delivering additional weight loss, a clinically meaningful distinction given the difficulties people with type 2 diabetes face in losing weight. The pivotal TRIUMPH-1 obesity readout is expected later in Q2 2026, with detailed TRANSCEND-T2D-1 results to be presented at the American Diabetes Association Scientific Sessions in June.
In vivo cell and gene therapy platform build: Lilly announced agreements to acquire four clinical-stage companies in a single quarter — Orna Therapeutics (circular RNA-based in vivo CAR-T for B-cell-driven autoimmune diseases), Kelonia Therapeutics (lentiviral in vivo CAR-T for multiple myeloma and other cancers), Centessa Therapeutics (JAK2 inhibitors), and Ajax Therapeutics (a Phase I JAK2 inhibitor for myelofibrosis and polycythemia vera). Skovronsky also confirmed the completed acquisition of Ventyx Biosciences, adding two NLRP3 inhibitors to the Lilly pipeline. Taken together, the transactions represent a deliberate pivot toward non-incretin, next-generation modalities across oncology and immunology, with Lilly deploying capital against in vivo cell engineering at an industry leading pace.
Eloralintide (LY3841136; selective amylin receptor agonist) Phase III expansion: The company initiated three new Phase III programs for eloralintide this quarter, adding knee osteoarthritis pain, obstructive sleep apnea, and an add-on therapy for obesity to the existing obesity Phase III program. Skovronsky described eloralintide's Phase II profile as offering GLP-1-like weight loss with improved tolerability, positioning it as both a non-GLP-1 mechanism alternative and a potential combination backbone. The breadth of the Phase III commitment — four indications now in late-stage development — based on Phase II tolerability signals introduces meaningful late-stage attrition risk if the tolerability advantage does not replicate at scale.
Analyst Pressure Points
Foundayo (orforglipron) launch trajectory versus oral Wegovy: Analysts pressed management on whether the early launch metrics for Foundayo were tracking below the trajectory of oral semaglutide (Wegovy), given that Foundayo is a new molecule, a new brand, and the first oral GLP-1 approved with obesity as the primary indication. Goldman Sachs analyst Asad Haider noted that the initial launch curve was expected to lag oral Wegovy before accelerating in the second half of the year, and asked management to characterize their confidence in that framing with three weeks of data. Ilya Yuffa, President of Lilly USA, said 20,000 patients had been treated to date, that 80% of Foundayo prescriptions were new to class, and that commercial access at two of the three largest pharmacy benefit managers would be confirmed by mid-May. Management did not revise the launch curve framing, and the guidance increase was attributed to the underlying performance of Mounjaro (tirzepatide) and Zepbound (tirzepatide) rather than Foundayo contribution.